AzTrials
AzTrials

Lower Extremity EdemaNCT07760363

Pedal Pump Clinical Trial on Edema V1

A study testing Pedal Pump in people with Lower Extremity Edema and Congestive Heart Failure(CHF), run by David McVay at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Previous research on the osteopathic manual technique entitled "Pedal Pump" has shown health benefits, specifically increasing lymphatic flow, decreasing lower extremity edema, and decreasing serum lactic acid after maximal exercise. However, due to the limitation of human practitioners, research has been limited. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Pedal Pump
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
60 participants
Where
1 siteUnited States
Study dates
6 Aug 2026to 31 Oct 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Bilateral lower extremity edema of at least mild severity judged by the treating clinician to be due to CHF, chronic venous insufficiency, kidney disease, or other etiologies of fluid overload conditions.
  • Medically stable
  • Able to remain in Fowler position for 10 minutes
  • Patients in the ER, observation, or admitted to the hospital for any period of time; outpatients (specifically CHF clinic patients)
  • Patients must give informed consent to participate. The patient must be able to read the consent form (in English or Spanish) or give consent after the form is translated for the patient.

Who cannot join

  • Patients using a hospital bed which has the scale on the foot board
  • Lymphedema (interstitial protein-built fluid)
  • Lipedema (fat distribution)
  • Pressure ulcers
  • Active DVT (i.e. Patients who have signs of acute unilateral swelling must have a documented negative lower extremity venous duplex ultrasound within the current admission before they will be included in the trial.)
  • Symptomatic peripheral vascular disease
Show all 14Show fewer
  • Wounds or infections in the feet, legs, buttocks, or back
  • Weeping lymphedema or bullous cellulitis
  • Uncontrolled hypertension (BP>180/110) in the recent 2 hours
  • Uncontrolled hypotension (BP <80/45) in the recent 2 hours
  • Heart rate greater than 110 or less than 45 in the recent 2 hours
  • Leg or back surgery in previous 30 days
  • Known pregnancy
  • Severe osteoporosis/fracture risk

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

United States1 site, 1 recruiting
  • Hillcrest Medical Center

    Tulsa, Oklahoma, 74104

    Dorene Taqi, 9185791072, dorene.taqi@hillcrest.com

    David W McVay, DO

    Recruiting

Other trials in United States

About this study

Previous research on the osteopathic manual technique entitled "Pedal Pump" has shown health benefits, specifically increasing lymphatic flow, decreasing lower extremity edema, and decreasing serum lactic acid after maximal exercise. However, due to the limitation of human practitioners, research has been limited.

The Pedal Pump is now a device which facilitates consistency in treatment and allows for increased sample size in research. This clinical trial studies the effects of 10 minutes of Pedal Pump treatment for hospitalized patients with lower extremity edema.

Read more

Key Question for this first study: Is the Pedal Pump a feasible treatment for hospitalized patients? Secondary question: Does the Pedal Pump decrease lower extremity edema?

This is a novel idea in its early stage of development, so Investigators anticipate product advancements, further testing with larger population sizes, and future publications.

Read the detailed description

The Pedal Pump is a device which engages the feet of patients while they are in bed. The device is placed between the foot board and the patient's feet. It provides gentle, on-and-off pressure to the feet, which, in turn, mobilizes the whole body in a rhythmic, calming manner.

The proposed hypotheses of the Pedal Pump are primarily based on the health benefits provided by normal walking. They include, but are not limited to…

Physiological Benefits

  • Increase lymphatic flow within the body
  • Increase blood flow back to the heart and into the tissues
  • Increase intestinal peristalsis
  • Increase kidney filtration
  • Increase myofascial and musculoskeletal movement

Proposed Patient-Centered Benefits

  • Decrease lower extremity fluid volume
  • Decrease lower back pain
  • Decrease neck pain
  • Increase return of bowel function after intra-abdominal surgery

For this first, feasibility study the Investigators will be investigating if the Pedal Pump is tolerated by hospitalized patients, and if so, does it decrease lower extremity edema.

Treatment:

  • Patients will lay with the head of the bed elevated at a 45-60 degree angle (i.e., in Fowler's position)
  • Patients will receive the Pedal Pump treatment applied to both feet for 10 minutes continuously, provided the treatment is tolerated by the patient.

Objective Measures: Assessments of the feet and legs will be taken pre-treatment (Minute 0), post-treatment (Minute 10-15), and follow-up (45-60 minutes after post-treatment):

  • Feet: skin redness, bruising, swelling, numbness, capillary refill
  • Bilateral Mid-Thigh Circumferences (15 cm above superior patella), Mid-Calf Circumferences (largest circumference), Ankle Circumferences (superior to the malleoli)
  • The Assessor will use a skin marker to mark the location where he or will measure, marking horizontal lines above and below the measuring tape over the ankle, calf, and mid-thigh. He or she will use the same location for pre-treatment, post-treatment, and follow-up measurements. Each circumference measurement will be obtained in a duplicate. The average of the two measurements will be used for analysis.
  • The measuring tape will not have slack and will not be so tight to cause pitting edema.

Subjective Measures: The below Symptoms will be rated by the patient pre-treatment, post-treatment, and at follow-up. Ratings range from 0 (none), 1 (mild), 2 (moderate), 3 (severe).

  • Foot pain
  • Ankle pain
  • Knee pain
  • Upper leg pain
  • Low back pain
  • Mid back pain
  • Upper back pain
  • Neck Pain
  • Headache
  • Nausea
  • Stress level

Thresholds for clinically meaningful change:

  • Circumference change ≥1 cm
  • Pain, headache, nausea, or stress level changes ≥1 points

Treatment vs Sham

  • 40 patients (⅔) receiving the Treatment and 20 patients (⅓) receiving the Sham.
  • Randomization will occur via 60 sealed envelopes shuffled and then distributed to the Operators.

Routine care

  • Patients will socialize, watch TV, read a book, use their phones or laptops, or otherwise spend their time how they prefer. However, unless there is an adverse outcome or the treatment needs to be aborted, they will keep their feet connected to the heel protector pillows which will be engaging the device during the entire 10 minutes.
  • Patients will continue to receive diuretics and other treatment for lower extremity edema. Because the effects of medicines on lower extremity edema are usually seen in hours and not minutes. In other words, if a significant effect is shown within 10 minutes while the device is activated, then the effect would have been from the Pedal Pump's treatment in those 10 minutes.
  • Both Treatment and Control (Sham) groups will receive new measurements and surveys 45-60 minutes after the treatment, including asking them which group they believed they were included in (i.e. treatment vs. control) and their level of confidence in that belief.

Data Storage and Analysis:

  • The initial data will be written on paper by the patients and clinical assessors. Papers will be collected by the Hillcrest Pedal Pump Investigation team. Papers will be scanned into PDF for storage in a HIPAA-compliant Google Drive Folder. The data collected (without patient identifiers) will then be manually uploaded to HIPAA-compliant Google Sheets or Microsoft Excel.
  • Investigators will use a Double Data Entry protocol (two different people type the data, and a system checks for mismatches) to ensure data integrity.

Statistical methods:

  • Continuous variables (circumferences) will be analyzed by a blinded statistician using a paired t-test (pre vs. post) and an independent t-test or repeated measures ANOVA to compare the Treatment group directly against the Sham control group.
  • Investigators will analyze the Subjective and Objective measures to establish standard deviation, p-values, and confidence intervals to define clinical significance.

Handling of missing data:

  • If a patient or an assessor does not complete 30% or more of questions on the forms, the entry will be voided altogether.
  • Investigators will use an Intention-to-Treat Analysis (i.e., analyzing all subjects' data to discover how the device may be experienced in real life by different hospitalized subjects).

Device Description and Engineering Safety

  • Device mechanism: Applying a cephlad-directed load to the plantar surfaces of the feet without causing dorsiflexion.
  • Mechanical specifications: A 3D printed platform and casing with a motor inside and on-off switch outside of the casing. See video below for visual details.

Device Specifications

  • Power source is provided from a standard USA electrical outlet (120V). Power cord includes an AC / DC Adapter. Input: 100-240V. Output: 20-24V with 3-5 amp input into motor. Frequency/power: Device moves laterally with frequency of 1 cycle every 1.5 seconds and a max torque of 160 kg-cm.
  • Contact materials: Patients' feet will be in socks of the patient's choice which will contact the plastic covers of the heel protector pillows. The heel protector pillows will contact the Pedal Pump platform.
  • Safety: If a small internal piece of the device breaks, the patient will be protected by the device's platform and then additional protection from heel protector pillows.
  • Emergency Stop: If the patient has a need for emergent cessation of treatment, the patient can at any time move his or her feet away from the device (i.e. there is not any restraint placed on the patient's feet). The Operator can also turn off the device at any moment.
Being tested
Pedal Pump, Pedal Pump Sham
Keywords
Pedal Pump, Lower Extremity Edema, Congestive Heart Failure, CHF, LE Edema
Medical subject headings
Heart Failure, Kidney Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Pedal PumpDevice

    Also called Foot Pump, Foot Mobilizer, Feet Mover

    The Pedal Pump device pumps both feet for 10 minutes continuously-- mobilizing their whole body in sufficient manner to see the nose move.

  • Pedal Pump ShamDevice

    The Sham Intervention is the same as Pedal Pump Intervention with the exact same Pedal Pump device generating identical operational sounds and visible movement; however, the patient's body will not be close enough to the device to produce sufficient displacement to transmit mechanical forces beyond the feet. The Pedal Pump will only contact the heel protector pillows enough to make the toes move but will not contact them enough to mobilize the legs or the entire body.

Study groups in NCT07760363
Study groupRoleWhat they receive
Treatment GroupExperimentalThe Treatment group will experience the Pedal Pump intervention by... 1. Being assisted to sit up in their beds at a 45-60 degree Fowler's position. Their thighs, calves, and ankles being marked with a surgical marker at the locations and measured. 2. The heel protector pillows being attached to their feet and the Pedal Pump being placed at the foot of the bed. 3. Provided the treatment is tolerated by the patient, the Pedal Pump treatment being applied to both feet for 10 minutes continuously mobilizing their whole body in sufficient manner to see the nose move. 4. The Operator turning off the device and removing it from the bed.
Receives: Device: Pedal Pump
Sham (Control) GroupSham comparatorThe Sham Group will have the same experience as Treatment Group with the exact same device generating identical operational sounds and visible movement, but the patient's body will not be close enough to the device to produce sufficient displacement to transmit mechanical forces beyond the feet. The Pedal Pump will only contact the heel protector pillows enough to make the toes move but will not contact them enough to mobilize the legs or the entire body.
Receives: Device: Pedal Pump Sham

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. No Treatment-Related Adverse Events Scoring 3, 4, or 5 on the CTCAE v4.0 scale

    Treatment-related adverse events will be assessed by CTCAE v4.0 on a 1-5 scale:

    • Grade 1 (Mild): Asymptomatic or mild symptoms.
    • Grade 2 (Moderate): Minimal, local, or noninvasive intervention indicated.
    • Grade 3 (Severe): Severe but not immediately life-threatening; hospitalization indicated.
    • Grade 4 (Life-threatening): Urgent intervention indicated.
    • Grade 5 (Death): Death related to the AE.

    Adverse Events monitors will be such as, but not limited to:

    • New pain
    • Worsened pain
    • Dizziness
    • Blood pressure instability
    • Skin irritation
    • Muscle cramping
    • Abdominal cramping
    • Anxiety
    • Nausea
    • Syncope
    • Chest pain of cardiac origin
    • Sustained arrhythmia
    • Stroke symptoms
    • Hypoxia
    • Hypotension

    Treatment will stop immediately if a Grade 3, 4, or 5 adverse event occurs. The Investigators will keep record of the number of patients having adverse events and their severities.

    Measured: 10 minutes

  2. Treatment Tolerability

    ≥95% treatment tolerability (<5% "aborted" treatments)

    Measured: 10 minutes

  3. Change in Lower Extremity Edema

    ≥1 cm change in average lower extremity circumferences

    Measured: 10 minutes

Secondary outcomes (2)
  1. No increase in pain or stress in ≥80% of the treatment group

    No increase in pain or stress in ≥80% of the treatment group per patient-reported symptoms using a scale of 0 (none), 1 (mild), 2 (moderate), or 3 (severe)

    Measured: 10 minutes

  2. <20% of Treatment Group having Treatment-Related Adverse Events scoring 2 per CTCAE v4.0

    Treatment-related adverse events will be assessed by CTCAE v4.0 on a 1-5 scale:

    • Grade 1 (Mild): Asymptomatic or mild symptoms.
    • Grade 2 (Moderate): Minimal, local, or noninvasive intervention indicated.
    • Grade 3 (Severe): Severe but not immediately life-threatening; hospitalization indicated.
    • Grade 4 (Life-threatening): Urgent intervention indicated.
    • Grade 5 (Death): Death related to the AE.

    Adverse Events monitors will be such as, but not limited to:

    • New pain
    • Worsened pain
    • Dizziness
    • Blood pressure instability
    • Skin irritation
    • Muscle cramping
    • Abdominal cramping
    • Anxiety
    • Nausea
    • Syncope
    • Chest pain of cardiac origin
    • Sustained arrhythmia
    • Stroke symptoms
    • Hypoxia
    • Hypotension

    Measured: 10 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Aug 2026
  2. Study start6 Aug 2026
  3. Primary completion30 Sep 2026 (estimated)
  4. Study completion31 Oct 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07760363
Sponsor's protocol ID
Hillcrest
Status last verified
Aug 2026
First submitted
5 Aug 2026
Last updated
12 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: * Age * Sex * Weight * BMI * Receiving IV diuretics * Receiving oral diuretics * Active CHF * Active chronic venous insufficiency * Acute kidney disease * Chronic kidney disease * End Stage Renal Disease (ESRD) * Active Hypertension * History of Myocardial infarction * History of Stroke * Active Diabetes * Smoking 5+ years history * Active pain

Questions about this trial

What is this clinical trial studying?

A study testing Pedal Pump in people with Lower Extremity Edema and Congestive Heart Failure(CHF), run by David McVay at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 12 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact David W McVay, DO (918-376-0107, davidwilliammcvay@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

No Treatment-Related Adverse Events Scoring 3, 4, or 5 on the CTCAE v4.0 scale (time frame: 10 minutes). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in